Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

BACKGROUND: This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Roca, Carlos, Cassier, Philippe, Zamarin, Dmitriy, Machiels, Jean-Pascal, Luis Perez Gracia, Jose, Stephen Hodi, F, Taus, Alvaro, Martinez Garcia, Maria, Boni, Valentina, Eder, Joseph P, Hafez, Navid, Sullivan, Ryan, Mcdermott, David, Champiat, Stephane, Aspeslagh, Sandrine, Terret, Catherine, Jegg, Anna-Maria, Jacob, Wolfgang, Cannarile, Michael A, Ries, Carola, Korski, Konstanty, Michielin, Francesca, Christen, Randolph, Babitzki, Galina, Watson, Carl, Meneses-Lorente, Georgina, Weisser, Martin, Rüttinger, Dominik, Delord, Jean-Pierre, Marabelle, Aurelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114963/
https://www.ncbi.nlm.nih.gov/pubmed/35577503
http://dx.doi.org/10.1136/jitc-2021-004076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114963/
https://www.ncbi.nlm.nih.gov/pubmed/35577503
http://dx.doi.org/10.1136/jitc-2021-004076

Ejemplares similares